Illumina Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 116 shares of the business’s stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $182.38, for a total value of $21,156.08. Following the completion of the transaction, the senior vice president now directly owns 39,900 shares in the company, valued at $7,276,962. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Charles Dadswell also recently made the following trade(s):
- On Wednesday, July 27th, Charles Dadswell sold 8,632 shares of Illumina stock. The stock was sold at an average price of $155.00, for a total value of $1,337,960.00.
Shares of Illumina Inc. (NASDAQ:ILMN) opened at 184.85 on Tuesday. The firm has a market capitalization of $27.10 billion, a P/E ratio of 63.30 and a beta of 0.47. Illumina Inc. has a 52 week low of $127.10 and a 52 week high of $196.47. The company has a 50-day moving average of $175.01 and a 200 day moving average of $156.56.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. During the same quarter last year, the firm earned $0.80 earnings per share. Illumina’s quarterly revenue was up 11.3% on a year-over-year basis. Equities research analysts anticipate that Illumina Inc. will post $3.53 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in ILMN. Capital Research Global Investors increased its position in shares of Illumina by 17.1% in the second quarter. Capital Research Global Investors now owns 13,085,071 shares of the life sciences company’s stock worth $1,836,882,000 after buying an additional 1,910,346 shares in the last quarter. Capital World Investors increased its position in shares of Illumina by 218.0% in the second quarter. Capital World Investors now owns 1,463,000 shares of the life sciences company’s stock worth $205,376,000 after buying an additional 1,003,000 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Illumina by 3.8% in the second quarter. Baillie Gifford & Co. now owns 18,615,061 shares of the life sciences company’s stock worth $2,613,182,000 after buying an additional 682,010 shares in the last quarter. Rockefeller Financial Services Inc. increased its position in shares of Illumina by 11,812.5% in the second quarter. Rockefeller Financial Services Inc. now owns 271,962 shares of the life sciences company’s stock worth $38,177,000 after buying an additional 269,679 shares in the last quarter. Finally, Eaton Vance Management increased its position in shares of Illumina by 1,107.7% in the second quarter. Eaton Vance Management now owns 196,643 shares of the life sciences company’s stock worth $27,605,000 after buying an additional 180,361 shares in the last quarter. 95.22% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on the company. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating in a report on Monday, July 4th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Illumina in a report on Wednesday, June 29th. Mizuho upped their price objective on Illumina from $138.00 to $148.00 and gave the stock a “neutral” rating in a report on Wednesday, July 27th. Canaccord Genuity set a $165.00 price objective on Illumina and gave the stock a “hold” rating in a report on Friday. Finally, Vetr downgraded Illumina from a “buy” rating to a “sell” rating and set a $142.96 price objective on the stock. in a report on Tuesday, July 26th. One analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $165.56.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.